We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Test Predicts Diabetes Mellitus Type 1 Risk

By LabMedica International staff writers
Posted on 04 Jul 2013
Type 1 diabetes usually has a preclinical phase identified by circulating islet autoantibodies, but the rate of progression to diabetes after seroconversion to islet autoantibodies is equivocal.

Diabetes mellitus type 1 can occur at any age and it starts with the immune system destroying insulin-producing beta cells, which eventually stops the production of insulin and without insulin the body cannot control blood sugar or glucose. More...


Scientists based at the Helmholtz Zentrum (Munich, Germany) gathered data from three different studies, which included a total of 13,377 children. The study involved analyzing blood samples taken from children to identify any preclinical clues that indicate any increased risk of type 1 diabetes. Two diabetes-related autoantibodies were found to be the strongest indicators of diabetes risk.

The children’s genetic risk for type 1 diabetes was estimated by measuring the development of insulin autoantibodies, glutamic acid decarboxylase 65 (GAD65) autoantibodies, and insulinoma antigen 2 (IA2) autoantibodies. At the 10-year follow-up, an overwhelming 70% of the children with multiple islet autoantibodies developed type 1 diabetes, compared to 15% among those with just one autoantibody.

At follow-up, 8% of the children had one or more of the autoantibodies, indicators for the destruction of insulin, 585 children had at least two autoantibodies and 474 were found to have just one. Nearly half of the children with two or more autoantibodies went on to develop diabetes within five years, and four out of every five of them became diabetic within fifteen years. Only 14.5% of children with just one autoantibody developed type 1 diabetes after 10 years.

The authors concluded that the detection of multiple islet autoantibodies in children who are genetically at risk marks a preclinical stage of type 1 diabetes. Thus, the development of multiple islet autoantibodies in children predicts type 1 diabetes. Future prevention studies should focus on this high-risk population.

"Jay S. Skyler, MD, and Jay M. Sosenko, MD, both from the Leonard M. Miller School of Medicine (Miami, FL, USA) wrote in an accompanying editorial: "If you have two or more autoantibodies, it's nearly inevitable that you will develop the disease. Most people, even physicians, don't appreciate this risk." The study was published on June 19, 2013, in the Journal of the American Medical Association.

Related Links:
Helmholtz Zentrum
Leonard M. Miller School of Medicine



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.